Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.

[1]  Santi Ranjan Pal,et al.  Non-parametric Test , 2015 .

[2]  G. Kimura,et al.  Circadian rhythm of urinary potassium excretion during treatment with an angiotensin receptor blocker , 2014, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[3]  S. Bansal,et al.  Use of natriuretic-doses of spironolactone for treatment of loop diuretic resistant acute decompensated heart failure. , 2014, International journal of cardiology.

[4]  A. Jaffe,et al.  Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. , 2013, Clinical biochemistry.

[5]  K. Swedberg,et al.  Serum aldosterone is associated with mortality and re‐hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial , 2013, European journal of heart failure.

[6]  T. Richards,et al.  Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. , 2013, International journal of cardiology.

[7]  I. Os,et al.  The Cardiorenal Syndrome: What the Cardiologist Needs to Know , 2013, Cardiology.

[8]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[9]  J. Ferreira,et al.  Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors , 2013, Clinical Research in Cardiology.

[10]  P. Ponikowski,et al.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial , 2013, European heart journal.

[11]  C. O'connor,et al.  Markers of Decongestion, Dyspnea Relief, and Clinical Outcomes Among Patients Hospitalized With Acute Heart Failure , 2013, Circulation. Heart failure.

[12]  Yukihito Sato,et al.  Early Evolution and Correlates of Urine Albumin Excretion in Patients Presenting With Acutely Decompensated Heart Failure , 2013, Circulation. Heart failure.

[13]  S. Kimmel,et al.  Blood Urea Nitrogen/Creatinine Ratio Identifies a High-Risk but Potentially Reversible Form of Renal Dysfunction in Patients With Decompensated Heart Failure , 2013, Circulation. Heart failure.

[14]  P. Ponikowski,et al.  Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.

[15]  J. Núñez Villota,et al.  [Red cell distribution width and mortality risk in acute heart failure patients]. , 2013, Medicina clinica.

[16]  K. Anstrom,et al.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.

[17]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[18]  I. Piña,et al.  Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. , 2012, European heart journal.

[19]  John A Kellum,et al.  Acute kidney injury , 2012, The Lancet.

[20]  V. Hasselblad,et al.  Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study , 2011, European journal of heart failure.

[21]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[22]  M. Gheorghiade,et al.  Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. , 2011, European heart journal.

[23]  Carlo Lombardi,et al.  Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure: Analysis From the PROTECT Pilot Study , 2011, Circulation. Heart failure.

[24]  P. Loria,et al.  The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism , 2011, Journal of Translational Medicine.

[25]  C. Brensinger,et al.  Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. , 2011, Journal of the American College of Cardiology.

[26]  A. Köttgen,et al.  High-normal albuminuria and risk of heart failure in the community. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  S. Manzano-Fernández,et al.  Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.

[28]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[29]  J. P. Araújo,et al.  Prognostic Implications of Diuretic Dose in Chronic Heart Failure , 2011, Journal of cardiovascular pharmacology and therapeutics.

[30]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[31]  A. Kazory.  Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. , 2010, The American journal of cardiology.

[32]  P. Ponikowski,et al.  Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward , 2010, Circulation. Heart failure.

[33]  L. Tavazzi,et al.  Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure: Data From the GISSI-Heart Failure Trial , 2010, Circulation. Heart failure.

[34]  P. Schulze,et al.  Episodes of Acute Heart Failure Syndrome Are Associated With Increased Levels of Troponin and Extracellular Matrix Markers , 2010, Circulation. Heart failure.

[35]  Nobuaki Kobayashi,et al.  Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure. , 2010, International heart journal.

[36]  R. Schrier,et al.  Cardiorenal syndrome in acute decompensated heart failure. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[37]  Minoru Horie,et al.  Serum Cortisol as a Useful Predictor of Cardiac Events in Patients With Chronic Heart Failure: The Impact of Oxidative Stress , 2009, Circulation. Heart failure.

[38]  J. Mullins,et al.  Mineralocorticoid and Glucocorticoid Receptors Stimulate Epithelial Sodium Channel Activity in a Mouse Model of Cushing Syndrome , 2009, Hypertension.

[39]  S. Manzano-Fernández,et al.  Red blood cell distribution width predicts long‐term outcome regardless of anaemia status in acute heart failure patients , 2009, European journal of heart failure.

[40]  S. Solomon,et al.  Albuminuria in chronic heart failure: prevalence and prognostic importance , 2009, The Lancet.

[41]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[42]  S. Navaneethan,et al.  Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[43]  M. Jessup,et al.  The cardiorenal syndrome: do we need a change of strategy or a change of tactics? , 2009, Journal of the American College of Cardiology.

[44]  G. Navis,et al.  Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. , 2009, Journal of the American College of Cardiology.

[45]  M. Gheorghiade,et al.  Acute heart failure syndromes , 2009, Journal of the American College of Cardiology.

[46]  C. O'connor,et al.  Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil? , 2009, Circulation. Heart failure.

[47]  M. Gekle,et al.  Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? , 2009, Pflügers Archiv - European Journal of Physiology.

[48]  W. White,et al.  Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. , 2008, Journal of the American Society of Hypertension : JASH.

[49]  W. Peacock,et al.  Impact of Intravenous Loop Diuretics on Outcomes of Patients Hospitalized with Acute Decompensated Heart Failure: Insights from the ADHERE Registry , 2008, Cardiology.

[50]  L. Ruilope,et al.  Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) , 2008, Circulation.

[51]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[52]  R. Schrier.  Blood urea nitrogen and serum creatinine: not married in heart failure. , 2008, Circulation. Heart failure.

[53]  M. Mani,et al.  The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease , 2008, Nephrology.

[54]  P. Brandish,et al.  Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats. , 2008, Journal of pharmacological and toxicological methods.

[55]  Nicola Parenti,et al.  Cardiac troponin I as prognostic marker in heart failure patients discharged from emergency department , 2008, Internal and emergency medicine.

[56]  S. Gottlieb,et al.  Diuretics: Still the mainstay of treatment , 2008, Critical care medicine.

[57]  Wenhan Wan,et al.  Effect of Post–Myocardial Infarction Exercise Training on the Renin-Angiotensin-Aldosterone System and Cardiac Function , 2007, The American journal of the medical sciences.

[58]  C. Specchia,et al.  The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT‐proBNP and cardiac troponin‐T , 2007, European journal of heart failure.

[59]  M. Pfeffer,et al.  Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. , 2007, Journal of the American College of Cardiology.

[60]  R. Taniguchi,et al.  Persistently increased serum concentrations of cardiac troponin in patients with acutely decompensated heart failure are predictive of adverse outcomes. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[61]  M. Gheorghiade,et al.  A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. , 2007, European heart journal.

[62]  A. Mebazaa,et al.  Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy , 2007, Heart Failure Reviews.

[63]  M. Weir.  Microalbuminuria and cardiovascular disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[64]  Stefan Störk,et al.  Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure , 2007, Circulation.

[65]  Peter C Austin,et al.  Relation between cardiac troponin I and mortality in acute decompensated heart failure. , 2007, American heart journal.

[66]  L. Navar,et al.  Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension. , 2007, American journal of physiology. Renal physiology.

[67]  G. Bakris,et al.  Microalbuminuria: What Is It? Why Is It Important? What Should Be Done About It? An Update , 2007, Journal of clinical hypertension.

[68]  M. Knepper,et al.  Urea and renal function in the 21st century: insights from knockout mice. , 2007, Journal of the American Society of Nephrology : JASN.

[69]  G. Montalescot,et al.  High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction , 2006, Circulation.

[70]  J. Ménard,et al.  Investigation of aldosterone-synthase inhibition in rats , 2006, Journal of hypertension.

[71]  R. Schmieder,et al.  Rapid Nongenomic Effects of Aldosterone on the Renal Vasculature in Humans , 2006, Hypertension.

[72]  R. Schrier.  Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? , 2006, Journal of the American College of Cardiology.

[73]  P. Raskin,et al.  Differential Effects of &bgr;-Blockers on Albuminuria in Patients With Type 2 Diabetes , 2005 .

[74]  E. Maltezos,et al.  Levosimendan Use Reduces Matrix Metalloproteinase-2 in Patients with Decompensated Heart Failure , 2005, Cardiovascular Drugs and Therapy.

[75]  A. Voors,et al.  High prevalence of microalbuminuria in chronic heart failure patients. , 2005, Journal of cardiac failure.

[76]  W. Colucci,et al.  Cardioprotection: a new paradigm in the management of acute heart failure syndromes. , 2005, The American journal of cardiology.

[77]  Gerasimos Filippatos,et al.  Pathophysiologic targets in the early phase of acute heart failure syndromes. , 2005, The American journal of cardiology.

[78]  G. Keren,et al.  Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. , 2005, American heart journal.

[79]  N. Brown.  Aldosterone and end-organ damage. , 2005, Current opinion in nephrology and hypertension.

[80]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[81]  Douglas L Mann,et al.  Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.

[82]  Karen A. Hartman,et al.  Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. , 2005, Clinical chemistry.

[83]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[84]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[85]  J. Stokes,et al.  Sodium retention in cirrhotic rats is associated with increased renal abundance of sodium transporter proteins. , 2005, Kidney international.

[86]  D. Sica.  Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis , 2005, Heart Failure Reviews.

[87]  L. Bouter,et al.  Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction--the Hoorn Study. , 2004, Kidney international. Supplement.

[88]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[89]  J. Ramires,et al.  Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. , 2004, Journal of cardiac failure.

[90]  J. Cohn,et al.  The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. , 2004, European heart journal.

[91]  C. O'connor,et al.  Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. , 2004, American heart journal.

[92]  A. A. da Silva,et al.  Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration , 2004, Hypertension.

[93]  S. Tyagi,et al.  Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts , 1996, Molecular and Cellular Biochemistry.

[94]  H. Naruse,et al.  Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. , 2003, Clinical chemistry.

[95]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[96]  G. Fonarow,et al.  Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.

[97]  C. Brunelli,et al.  Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure , 2003, European journal of clinical investigation.

[98]  G. Biondi-Zoccai,et al.  Potential antiapoptotic activity of aldosterone antagonists in postinfarction remodeling. , 2003, Circulation.

[99]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[100]  A. Burger,et al.  Neurohormonal prediction of mortality following admission for decompensated heart failure. , 2003, The American journal of cardiology.

[101]  G. Fonarow,et al.  Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. , 2003, Reviews in cardiovascular medicine.

[102]  M. Gobbi,et al.  Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. , 2002, Journal of molecular and cellular cardiology.

[103]  A. Struthers.  Aldosterone: cardiovascular assault. , 2002, American heart journal.

[104]  D. Duprez,et al.  Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. , 2002, Journal of the American College of Cardiology.

[105]  A. Struthers,et al.  Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. , 2002, Clinical science.

[106]  R. Weiss,et al.  Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. , 2002, American journal of hypertension.

[107]  H. Krum,et al.  Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients , 2002, Hypertension.

[108]  M. Pfeffer,et al.  Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. , 2002, Journal of the American College of Cardiology.

[109]  D. Ellison.  Diuretic Therapy and Resistance in Congestive Heart Failure , 2002, Cardiology.

[110]  K. Weber.  Aldosterone in congestive heart failure. , 2001, The New England journal of medicine.

[111]  F. Spinale,et al.  Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. , 2001, American journal of physiology. Heart and circulatory physiology.

[112]  P. Palatini,et al.  Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality. , 2001, European heart journal.

[113]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[114]  D. Ellison,et al.  Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. , 2001, Journal of the American Society of Nephrology : JASN.

[115]  F. Spinale,et al.  Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure , 2001, Circulation.

[116]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[117]  F. Spinale,et al.  A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure , 2000, Circulation.

[118]  J. Ketelslegers,et al.  Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. , 2000, Journal of cardiac failure.

[119]  K. Denton,et al.  Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[120]  E. Ritz,et al.  Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. , 2000, Journal of the American Society of Nephrology : JASN.

[121]  S. Yusuf,et al.  Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. , 2000, Diabetes care.

[122]  A. Delcourt,et al.  Altered balance between matrix gelatinases (MMP‐2 and MMP‐9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP‐9 in myosin‐heavy chain degradation , 1999, European journal of heart failure.

[123]  C. Blocher,et al.  Effect of increased renal venous pressure on renal function. , 1999, The Journal of trauma.

[124]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[125]  D. Mann,et al.  Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.

[126]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[127]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[128]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[129]  J. Romero Artaza,et al.  [Red cell distribution width (RDW): its use in the characterization of microcytic and hypochromic anemias]. , 1999, Medicina.

[130]  A. Ciampi,et al.  Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. , 1998, European heart journal.

[131]  J. Cohn,et al.  Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. , 1998, European heart journal.

[132]  F. Spinale,et al.  Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .

[133]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[134]  J. McEwan,et al.  Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.

[135]  J. Schnermann,et al.  Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion. , 1995, Hypertension.

[136]  K. Weber,et al.  Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. , 1994, Journal of molecular and cellular cardiology.

[137]  G. Lamas,et al.  N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.

[138]  L. Schild,et al.  Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits , 1994, Nature.

[139]  G. Aguilera.  Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[140]  R. Ardaillou,et al.  Glomerular effects of angiotensin II: a reappraisal based on studies with non-peptide receptor antagonists. , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[141]  A. Donker,et al.  Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. , 1993, The American journal of cardiology.

[142]  A. Branzi,et al.  Evidence of a Partial Escape of Renin‐Angiotensin‐Aldosterone Blockade in Patients with Acute Myocardial Infarction Treated with Ace Inhibitors , 1993, Journal of clinical pharmacology.

[143]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[144]  W. Abraham,et al.  Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. , 1991, American journal of nephrology.

[145]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[146]  M. Rogers,et al.  Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing Metabolites , 1989, Journal of clinical pharmacology.

[147]  J. Firth,et al.  RAISED VENOUS PRESSURE: A DIRECT CAUSE OF RENAL SODIUM RETENTION IN OEDEMA? , 1988, The Lancet.

[148]  E. Kékes.  Captopril in heart failure. , 1988, Acta physiologica Hungarica.

[149]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[150]  R. Tallarida,et al.  Chi-Square Test , 2020, Definitions.

[151]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[152]  F. Merkus,et al.  Influence of food on the bioavailability of spironolactone , 1986, Clinical pharmacology and therapeutics.

[153]  H. Rennke,et al.  Role for angiotensin II in an overt functional proteinuria. , 1986, Kidney international.

[154]  F. Merkus,et al.  New insights into the pharmacokinetics of spironolactone , 1985, Clinical pharmacology and therapeutics.

[155]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[156]  B. Michorowski,et al.  The renin-angiotensin--aldosterone system and the clinical course of acute myocardial infarction. , 1983, European heart journal.

[157]  R. Jacobs,et al.  Mineralocorticoid Effects of 9α-Fluorodeoxycorticosterone in Adrenalectomized Rats.∗ , 1960 .

[158]  R. Wégria,et al.  The pathogenesis of proteinuria in the acutely congested kidney. , 1955, The Journal of clinical investigation.

[159]  M. Maxwell,et al.  RENAL VENOUS PRESSURE IN CHRONIC CONGESTIVE HEART FAILURE. , 1950, The Journal of clinical investigation.

[160]  R. Wégria,et al.  Effect of increased renal venous pressure on renal function. , 1949, The American journal of physiology.